Biguanide-Derived Polymeric Nanoparticles Kill MRSA Biofilm and Suppress Infection In Vivo

Jianghua Li1, Wenbin Zhong1, Kaixi Zhang1

  • 1Centre for Antimicrobial Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, 637459 Singapore.

Insights

Novel nanoparticles effectively kill drug-resistant MRSA biofilms. These FTP nanoparticles show superior efficacy and biocompatibility compared to existing treatments, offering a promising new therapy for MRSA infections.

Area of Science:

  • Biomaterials Science
  • Infectious Diseases
  • Nanotechnology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat due to its resistance to antibiotics, exacerbated by biofilm formation.
  • Biofilms shield bacteria, making them highly tolerant to conventional antimicrobial treatments.
  • Developing effective strategies against MRSA biofilms is crucial for public health.

Purpose of the Study:

  • To develop and evaluate a novel nanoparticle (NP) system for combating MRSA biofilm infections.
  • To assess the efficacy and biocompatibility of these nanoparticles both in vitro and in vivo.
  • To investigate the potential of these NPs as an alternative therapeutic approach for MRSA infections.

Main Methods:

  • Fabrication of FTP NPs using Pluronic F-127, tannic acid, and polyhexamethylene biguanide (PHMB).
  • In vitro assessment of FTP NPs' bactericidal activity against MRSA USA300 biofilms.
  • In vivo evaluation using a murine excisional wound model and comparison with vancomycin treatment.
  • In vitro cytotoxicity assays on mammalian cells and in vivo acute toxicity studies in mice.

Main Results:

  • FTP NPs demonstrated significantly enhanced bactericidal activity against MRSA biofilms compared to PHMB alone, achieving a ~100-fold greater reduction in vitro.
  • In vivo studies showed FTP NPs reduced MRSA USA300 biofilm bacteria by 1.8 log10, outperforming vancomycin (0.8 log10 reduction).
  • FTP NPs exhibited lower cytotoxicity to mammalian cells than PHMB and showed no acute toxicity in mice at therapeutic doses.

Conclusions:

  • Biguanide-based FTP NPs are highly effective against MRSA biofilms in vitro and in vivo.
  • The developed NPs offer a promising, biocompatible alternative for treating challenging MRSA infections.
  • FTP NPs represent a significant advancement in the development of novel antimicrobial agents.